Literature DB >> 6251961

Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis.

M M Berman, N P Libbey, J H Foster.   

Abstract

Hepatocellular carcinoma, even when treated with operative resection, is generally regarded as uniformly fatal. Isolated reports of an unusual histologic variant characterized by polyglonal cells with a fibrous stroma (PCFS) suggest a more favorable outcome. Twelve cases of PCFS, representing the largest reported group, are presented. The mean age of the patients at the time of onset was 23.1 years and the male to female ratio was 1:2. Successful operative resection of the primary neoplasm and metastatic foci has resulted in a significant percentage of long-term survivors with a mean survival time of 68 months and two- and five-year survival rates of 82% and 63%, respectively. The variant shows cytologic similarity to differentiated hepatocellular carcinoma with a unique stromal appearance suggesting a pattern of fibrosis associated with focal nodular hyperplasia. Focal nodular hyperplasia is noted occasionally in the liver adjacent to PCFS. The possibility that PCFS represents an intermediate stage between focal nodular hyperplasia and the more malignant variants of hepatocellular carcinoma is discussed.

Entities:  

Mesh:

Year:  1980        PMID: 6251961     DOI: 10.1002/1097-0142(19800915)46:6<1448::aid-cncr2820460626>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

1.  Myofibroblasts in hepatitis B related cirrhosis and hepatocellular carcinoma.

Authors:  K Y Chau; M A Lily; P C Wu; W L Yau
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

2.  Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.

Authors:  A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

3.  Fibrolamellar hepatocellular carcinoma with biliary tumor thrombus: an unreported association.

Authors:  Anna Maria De Gaetano; Erida Nure; Ugo Grossi; Francesco Frongillo; Rosellina Russo; Fabio Maria Vecchio; Maria Carmen Lirosi; Gabriele Sganga; Carla Felice; Lorenzo Bonomo; Salvatore Agnes
Journal:  Jpn J Radiol       Date:  2013-07-13       Impact factor: 2.374

4.  Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.

Authors:  K Tanaka; T Honna; Y Kitano; T Kuroda; K Tanaka; N Morikawa; H Matsuda; N Kawashima; K Matsuoka; J Miyauchi
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

Review 5.  Liver transplantation for malignant tumors.

Authors:  B Koneru; A Cassavilla; J Bowman; S Iwatsuki; T E Starzl
Journal:  Gastroenterol Clin North Am       Date:  1988-03       Impact factor: 3.806

6.  Fibrolamellar hepatocellular carcinoma in mexican patients.

Authors:  Julian Arista-Nasr; Lisa Gutierrez-Villalobos; Juan Nuncio; Hector Maldonaldo; Leticia Bornstein-Quevedo
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

7.  Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma.

Authors:  J S Albaugh; E B Keeffe; W W Krippaehne
Journal:  Dig Dis Sci       Date:  1984-08       Impact factor: 3.199

Review 8.  Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: report of a case.

Authors:  K Okada; Y I Kim; K Nakashima; I Tada; T Yoshida; M Kobayashi; S Yokoyama
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

9.  Aggressive surgical management of fibrolamellar hepatocellular carcinoma.

Authors:  A W Hemming; B Langer; P Sheiner; P D Greig; B R Taylor
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

10.  Fibrolamellar carcinoma of the liver--a case report.

Authors:  T Imai; H Yokoi; T Noguchi; Y Kawarada; R Mizumoto
Journal:  Gastroenterol Jpn       Date:  1991-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.